CYTENA Bioprocess Solutions, a CELLINK company, has launched the S.NEST™, a state-of-the art microbioreactor that maximizes cell growth while monitoring and analyzing cell conditions from start to finish. Well-known for combining innovative bioscience technologies with best-in-class software development, CYTENA Bioprocess Solutions has developed their new microbioreactor to disrupt the field of cell line development (CLD).

Microbioreactors have been instrumental in a string of research breakthroughs in CLD for a range of downstream applications, but with the addition of real-time monitoring, the S.NEST is at the forefront of those advances. Furthermore, it boasts an impressive merger of enhanced features, including patented technology for reciprocating mixing, incubation chambers with individual environmental controls, a camera module for real-time pH and dissolved oxygen monitoring, powerful analytical software to crunch data, compatibility with 96-well or 24-well culture plates, and four chambers for the high-throughput culturing of as many as 384 wells at once.

CLD researchers looking to streamline upscaling and expansion workflows, which previously required weeks to complete, are sure to embrace the S.NEST’s unique suspension culturing nourished by a continuous supply of oxygen. As part of CYTENA’s extensive portfolio of single-cell instruments, the S.NEST will make highly efficient cell culturing results accessible to laboratories around the world.

“The S.NEST revolutionizes cell culturing workflows with its unique technology to increase efficiency and productivity for biologics production, drug screening and functional genomics,says Charles Tsai, PhD, CEO CYTENA Bioprocess Solutions.

For more information, please contact:

Erik Gatenholm, CEO    
Phone (US): +1 (650) 515 5566
Phone (Sweden): +46 73 267 00 00

E-mail: eg@cellink.com
Gusten Danielsson, CFO   
Phone (US): +1 (857) 332 2138
Phone (Sweden): +46 709-91 86 04  
E-mail:
gd@cellink.com

The information was submitted for publication, through the agency of the above contact persons, on July 19, 2021, at 08:00 (CEST).

About CELLINK

Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 2,000 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,700 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B. www.cellink.com   

 

From CELLINK to BICO

CELLINK has initiated the process to change name from CELLINK to BICO to better reflect the company’s strategy, bio convergence agenda and market position. Read more about the process for the name change in the press release that was sent out on July 7, 2021, www.cellink.com/investors/press-releases